BSD Medical (BSDM) Reports Clinical Study Demonstrates Threefold Increase in Tumor Destruction From the Addition of Hyperthermia for Advanced Rectal Cancer Patients
10/23/2012 9:24:44 AM
SALT LAKE CITY--(BUSINESS WIRE)--BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a leading provider of medical systems utilizing heat therapy to treat cancer, announced today that published study results demonstrate improved rates of complete pathological tumor response (no evidence of viable tumor in primary tumor and lymph nodes) in advanced rectal cancer patients from the addition of hyperthermia, delivered using the BSD-2000 Hyperthermia System. The researchers also reported that hyperthermia may provide enough reduction in tumor size (downstaging) to allow an increased rate of sphincter preservation surgery (which can allow patients to maintain normal rectal function) in a subgroup of patients with rectal tumors located lower in the gastrointestinal tract. Hyperthermia was added to standard preoperative radiochemotherapy (combined radiotherapy and chemotherapy) for 61 patients, and results were retrospectively compared to 45 patients with locally advanced rectal cancer who were treated with standard preoperative radiochemotherapy alone.
comments powered by